ISSN 2330-717X

New Potential Factor Contributing To Severity Of COVID-19 Identified

By

The University of Kent’s School of Biosciences and the Institute of Medical Virology at Goethe-University, Frankfurt am Main, have identified a protein that may critically contribute to severe forms of COVID-19.

SARS-CoV-2 is the coronavirus that causes COVID-19. While many individuals develop only mild or no symptoms upon SARS-CoV-2 infection, others develop severe, life-threatening disease.

Researchers have found that the infection of cells with SARS-CoV-2 results in increased levels of a protein called CD47 on the cell surface.

CD47 is a so-called ‘do not eat me’ signal to the immune system’s defences that protect cells from being destroyed. Virus-induced CD47 on the surface of infected cells is likely to protect them from immune system recognition, enabling the production of larger amounts of virus, resulting in more severe disease.

Well-known risk factors for severe COVID-19 such as older age and diabetes are associated with higher CD47 levels. High CD47 levels also contribute to high blood pressure, which is a large risk factor for COVID-19 complications such as heart attack, stroke, and kidney disease.

The data suggest that age and virus-induced high CD47 levels contribute to severe COVID-19 by preventing an effective immune response and increasing disease-associated tissue and organ damage.

Since therapeutics targeting CD47 are in development, this discovery may result in improved COVID-19 therapies.

Professor Martin Michaelis, University of Kent, said: ‘This is exciting. We may have identified a major factor associated with severe COVID-19. This is a huge step in combatting the disease and we can now look forward to further progress in the design of therapeutics.’

Professor Jindrich Cinatl, Goethe-University Frankfurt, said: ‘These additional insights into the disease processes underlying COVID-19 may help us to design better therapies, as well as appreciation for the importance of the breadth of research being conducted. Through this avenue, we have achieved a major breakthrough and exemplified that the fight against the disease continues.’

Click here to have Eurasia Review's newsletter delivered via RSS, as an email newsletter, via mobile or on your personal news page.

2 thoughts on “New Potential Factor Contributing To Severity Of COVID-19 Identified

  • September 26, 2021 at 3:02 am
    Permalink

    How long will it to get a “therapy” that seems to work. Then phase 1, phase 2 trials, produce and distribute it? 6 months?, 12 months? 2 years? More?

    Reply
  • September 26, 2021 at 5:45 am
    Permalink

    This would explain why some patients have adverse reactions to the vaccines. The body can’t tell the difference between a vaxx’d person and someone with the actual illness. In both cases it fails to attack the correct cells.
    Also explains why, for some, the vax doesn’t seem to stop infection nor does it always lessen the severity.

    Reply

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.